Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study

被引:40
作者
Donswijk, Maarten L. [1 ]
van Leeuwen, Pim J. [2 ]
Vegt, Erik [1 ,3 ]
Cheung, Zing [1 ]
Heijmink, Stijn W. T. P. J. [4 ]
van der Poel, Henk G. [2 ]
Stokkel, Marcel P. M. [1 ]
机构
[1] Netherlands Canc Inst, Dept Nucl Med, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands
[2] Netherlands Canc Inst, Dept Urol, Amsterdam, Netherlands
[3] Erasmus MC, Dept Radiol & Nucl Med, Rotterdam, Netherlands
[4] Netherlands Canc Inst, Dept Radiol, Amsterdam, Netherlands
关键词
PSMA; Prostate; Staging; Management; Impact; BONE-SCINTIGRAPHY; HBED-CC; GA-68-PSMA; METASTASES; RECURRENCE;
D O I
10.1186/s12885-020-07192-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundTo evaluate the impact of Gallium-68 [Ga-68] labeled prostate specific membrane antigen (PSMA) positron emission tomography (PET)/X-ray computed tomography (CT) compared with conventional imaging on staging and clinical management of men evaluated for primary prostate cancer (PCa).MethodsMen with newly diagnosed biopsy-proven PCa who had been staged with a conventional staging protocol including bone scintigraphy (BS) and additionally underwent [Ga-68]PSMA PET/CT, were evaluated retrospectively. Imaging findings from BS, magnetic resonance imaging (MRI) and/or CT were categorized regarding locoregional nodal (N) and distant metastasis (M) status as negative, positive or equivocal before and after addition of the information of PET/CT. Also, the imaging-based level of confidence (LoC) in correct assessment of N and M status was scored. Impact of PET/CT on clinical management was evaluated by the percentage of treatment category changes after PET/CT as determined in the multidisciplinary tumour board.ResultsSixty-four men with intermediate and high-risk PCa were evaluated. With additional information of PET/CT, N status was upstaged in 23%, and downstaged in 9%. M status was upstaged in 13%, and downstaged in 23%. A net increase in LoC of 20% was noted, mainly regarding M status.Treatment category changed from palliative to curative in 9%, and from curative to palliative in 3%. An undecided treatment plan changed to curative in 14%, as well as to palliative in another 9%. In total, a 36% treatment category change was noted.High negative predictive value of PET/CT for M status was indicated by 27 patients that underwent robot-assisted radical prostatectomy and reached postoperative biochemical disease-free status or had a likely other site of disease recurrence.ConclusionsPSMA PET/CT can cause considerable changes in N and M staging, as well as in management compared to conventional staging. Findings of this study support the replacement of BS and CT by PSMA PET/CT in staging primary PCa.
引用
收藏
页数:10
相关论文
共 24 条
  • [1] The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
    Afshar-Oromieh, Ali
    Avtzi, Eleni
    Giesel, Frederik L.
    Holland-Letz, Tim
    Linhart, Heinz G.
    Eder, Matthias
    Eisenhut, Michael
    Boxler, Silvan
    Hadaschik, Boris A.
    Kratochwil, Clemens
    Weichert, Wilko
    Kopka, Klaus
    Debus, Juergen
    Haberkorn, Uwe
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (02) : 197 - 209
  • [2] Initial Experience of 68Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy
    Budaeus, Lars
    Leyh-Bannurah, Sami-Ramzi
    Salomon, Georg
    Michl, Uwe
    Heinzer, Hans
    Huland, Hartwig
    Graefen, Markus
    Steuber, Thomas
    Rosenbaum, Clemens
    [J]. EUROPEAN UROLOGY, 2016, 69 (03) : 393 - 396
  • [3] Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer
    Calais, Jeremie
    Kishan, Amar U.
    Cao, Minsong
    Fendler, Wolfgang P.
    Eiber, Matthias
    Herrmann, Ken
    Ceci, Francesco
    Reiter, Robert E.
    Rettig, Matthew B.
    Hegde, John V.
    Shaverdian, Narek
    King, Chris R.
    Steinberg, Michael L.
    Czernin, Johannes
    Nickols, Nicholas G.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (11) : 1714 - 1721
  • [4] 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review
    Corfield, Julia
    Perera, Marlon
    Bolton, Damien
    Lawrentschuk, Nathan
    [J]. WORLD JOURNAL OF UROLOGY, 2018, 36 (04) : 519 - 527
  • [5] Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
    Eiber, Matthias
    Herrmann, Ken
    Calais, Jeremie
    Hadaschik, Boris
    Giesel, Frederik L.
    Hartenbach, Markus
    Hope, Thomas
    Reiter, Robert
    Maurer, Tobias
    Weber, Wolfgang A.
    Fendler, Wolfgang P.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (03) : 469 - 478
  • [6] Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade
    Emmett, Louise
    Yin, Charlotte
    Crumbaker, Megan
    Hruby, George
    Kneebone, Andrew
    Epstein, Richard
    Quoc Nguyen
    Hickey, Adam
    Ihsheish, Noah
    O'Neill, Gordon
    Horvath, Lisa
    Chalasani, Venu
    Stricker, Phillip
    Joshua, Anthony M.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (07) : 950 - 954
  • [7] 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
    Fendler, Wolfgang P.
    Eiber, Matthias
    Beheshti, Mohsen
    Bomanji, Jamshed
    Ceci, Francesco
    Cho, Steven
    Giesel, Frederik
    Haberkorn, Uwe
    Hope, Thomas A.
    Kopka, Klaus
    Krause, Bernd J.
    Mottaghy, Felix M.
    Schoder, Heiko
    Sunderland, John
    Wan, Simon
    Wester, Hans-Juergen
    Fanti, Stefano
    Herrmann, Ken
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (06) : 1014 - 1024
  • [8] Is there still a role for computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 database
    Gabriele, D.
    Collura, D.
    Oderda, M.
    Stura, I.
    Fiorito, C.
    Porpiglia, F.
    Terrone, C.
    Zacchero, M.
    Guiot, C.
    Gabriele, P.
    [J]. WORLD JOURNAL OF UROLOGY, 2016, 34 (04) : 517 - 523
  • [9] Gordon LG, 2018, UROL ONCOL, V36, P3
  • [10] 68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer
    Herlemann, Annika
    Wenter, Vera
    Kretschmer, Alexander
    Thierfelder, Kolja M.
    Bartenstein, Peter
    Faber, Claudius
    Gildehaus, Franz-Josef
    Stief, Christian G.
    Gratzke, Christian
    Fendler, Wolfgang P.
    [J]. EUROPEAN UROLOGY, 2016, 70 (04) : 553 - 557